Evidence, scope and corrections
Trace the claim to the product, then to its source.
These guides use US prescribing information and manufacturer pages for selected identity, indication and practical-use facts. Sources are linked next to the facts they support. A retrieval date is not a label revision date and is not evidence of pharmacy availability. No clinician reviewer, patient experience or commercial relationship with a drug manufacturer is claimed.
How answers are built
The opening answer is editorial synthesis. Product rows identify the ingredient, form and limited labeled role. Cost guides distinguish manufacturer program terms, primary pharmacy listings and secondary published cash-price references. Each amount identifies its product, quantity, source and check date; none is a personal pharmacy quote. We do not infer a head-to-head winner from separate placebo-controlled trials or a substitution approval from similar names.
Known limits
No live pharmacy quote, therapeutic-equivalence audit for every supplier, comprehensive label audit, or independent clinical review is provided. Product sources can change; use the current label and your clinician’s advice. We have not verified ranking, indexing or AI citation performance.
Product register
Veozah
fezolinetant · Oral tablet
Scope: Menopausal moderate-to-severe hot flashes. Selected facts checked 2026-09-15. Open product source
Lynkuet
elinzanetant · Oral capsule
Scope: Menopausal moderate-to-severe hot flashes. Selected facts checked 2026-09-15. Open product source
Brisdelle
paroxetine mesylate, 7.5 mg formulation · Oral capsule
Scope: Menopausal moderate-to-severe vasomotor symptoms. Selected facts checked 2026-09-15. Open product source
Paroxetine 7.5 mg
paroxetine mesylate · Oral capsule
Scope: Menopausal moderate-to-severe vasomotor symptoms. Selected facts checked 2026-09-15. Open product source
Oral estradiol
estradiol · Oral tablet
Scope: Includes menopausal vasomotor symptoms. Selected facts checked 2026-09-15. Open product source
Divigel
estradiol · Skin gel
Scope: Menopausal moderate-to-severe vasomotor symptoms. Selected facts checked 2026-09-15. Open product source
Minivelle
estradiol · Skin patch
Scope: Hot flashes and osteoporosis prevention; indication varies by strength. Selected facts checked 2026-09-15. Open product source
CombiPatch
estradiol + norethindrone acetate · Skin patch
Scope: Menopausal symptoms under the product label. Selected facts checked 2026-09-15. Open product source
Bijuva
estradiol + progesterone · Oral capsule
Scope: Moderate-to-severe menopausal vasomotor symptoms in women with a uterus. Selected facts checked 2026-09-15. Open product source
Duavee
conjugated estrogens + bazedoxifene · Oral tablet
Scope: Vasomotor symptoms and osteoporosis prevention in women with a uterus. Selected facts checked 2026-09-15. Open product source
Prometrium
micronized progesterone · Oral capsule
Scope: Endometrial hyperplasia prevention with estrogen in the labeled population. Selected facts checked 2026-09-15. Open product source
Generic progesterone
micronized progesterone · Oral capsule
Scope: Endometrial hyperplasia prevention with estrogen under this label. Selected facts checked 2026-09-15. Open product source
Vagifem
estradiol · Vaginal insert
Scope: Atrophic vaginitis due to menopause. Selected facts checked 2026-09-15. Open product source
Estring
estradiol · Vaginal ring
Scope: Moderate-to-severe menopausal vulvar and vaginal atrophy symptoms. Selected facts checked 2026-09-15. Open product source
Femring
estradiol acetate · Vaginal ring
Scope: Menopausal vasomotor symptoms and vulvovaginal atrophy. Selected facts checked 2026-09-15. Open product source
Estradiol vaginal cream
estradiol · Vaginal cream
Scope: Vulvar and vaginal atrophy symptoms. Selected facts checked 2026-09-15. Open product source
Osphena
ospemifene · Oral tablet
Scope: Moderate-to-severe menopausal vaginal dryness and/or painful intercourse. Selected facts checked 2026-09-15. Open product source
Intrarosa
prasterone · Vaginal insert
Scope: Moderate-to-severe menopausal dyspareunia due to vulvovaginal atrophy. Selected facts checked 2026-09-15. Open product source
Corrections and ownership context
This subdomain is built as a companion to MenopauseCalculator.com and directs visitors to that site’s tools. It should not be read as an independent rating service. No star ratings, patient reviews or manufacturer endorsements are used. Send a source correction through the main website.
Machine-readable records
Drug register JSON · Answer register JSON. These static files are snapshots, not live prescribing APIs.
Commercial evidence update
On 17 September 2026, 25 cost, comparison and access guides were rewritten using linked product labels, program terms, government guidance and identified price references. Three overlapping URLs were consolidated into existing guides. These content pages are eligible for indexing; inclusion in a sitemap does not guarantee search-engine indexing. Published offer amounts remain conditional, and secondary cash-price listings are not independently verified pharmacy quotes.